Minimal residual disease detection in multiple myeloma: current status, challenges and strategies
10.3760/cma.j.issn.1009-9921.2017.12.006
- VernacularTitle:多发性骨髓瘤微小残留病检测:现状、挑战与对策
- Author:
Chunyan SUN
1
;
Xuejiao YIN
;
Yu HU
Author Information
1. 华中科技大学同济医学院附属协和医院血液病研究所
- Keywords:
Multiple myeloma;
Neoplasm,residual;
Prognosis;
Multi-parameter flow cytometry
- From:
Journal of Leukemia & Lymphoma
2017;26(12):725-729
- CountryChina
- Language:Chinese
-
Abstract:
Long time clinical results have showed that multiple myeloma (MM) patients who achieved complete remission (CR) had heterogeneous prognosis. Some patients who achieved CR relapsed in a short time, even died within 2 years after initial therapy, while other patients acquired long-term survival. With the emergence of minimal residual disease (MRD) assessment, rigorous personal therapy monitoring and accurate prognostic evaluation could be realized. MRD can monitor inside the bone marrow by multi-parameter flow cytometry, allele-specific oligonucleotide-based quantitative polymerase chain reaction and next-generation sequencing, as well as the external conditions of the bone marrow by sensitive imaging techniques. This article focuses on clinical benefit, characteristics of different monitoring methods and future direction of MRD in MM.
